Editorials
Incomplete intrapulmonary lymph node retrieval after routine pathologic examination of resected lung cancer
Translational Lung Cancer Research
2013;
2
(1)
:1-2
.
(14 January 2013)
New insights into the functional consequences of ephrin A3 mutations in non-small cell lung cancer
Translational Lung Cancer Research
2013;
2
(1)
:3-5
.
(14 January 2013)
Original Article
Is overall survival still the primary endpoint in maintenance non-small cell lung cancer studies? An analysis of phase III randomised trials
Translational Lung Cancer Research
2013;
2
(1)
:6-13
.
(14 January 2013)
Review Articles
Inhibition of insulin-like growth factor receptor: end of a targeted therapy?
Translational Lung Cancer Research
2013;
2
(1)
:14-22
.
(14 January 2013)
MET inhibition in lung cancer
Translational Lung Cancer Research
2013;
2
(1)
:23-39
.
(14 January 2013)
Irreversible EGFR-TKIs: dreaming perfection
Translational Lung Cancer Research
2013;
2
(1)
:40-49
.
(14 January 2013)
EGFR TKIs
Does the order of factors affect the product? Lessons learned from the TORCH trial
Translational Lung Cancer Research
2013;
2
(1)
:50-54
.
(14 January 2013)
Keeping our fingers crossed on 2nd generation EGFR TKIs: is better good enough?
Translational Lung Cancer Research
2013;
2
(1)
:55-57
.
(14 January 2013)
Front-line erlotinib in unselected patients with advanced NSCLC and poor performance status - the TOPICAL study
Translational Lung Cancer Research
2013;
2
(1)
:58-61
.
(14 January 2013)
The TOPICAL study should be more topical!
Translational Lung Cancer Research
2013;
2
(1)
:62-63
.
(14 January 2013)
ZEPHYR Trial
ZEPHYR illustrates the perils of testing targeted treatments in unselected non-small-cell lung cancer patients
Translational Lung Cancer Research
2013;
2
(1)
:E1-E3
.
(14 January 2013)
ZEPHYR: failure of a “spring wind” in lung cancer
Translational Lung Cancer Research
2013;
2
(1)
:E4-E6
.
(14 January 2013)
Vandetanib in advanced non small cell lung cancer: a promise unfulfilled
Translational Lung Cancer Research
2013;
2
(1)
:E7-E9
.
(14 January 2013)
MONET-1 Trial
Antiangiogenic tyrosine kinase inhibitors in non-small-cell-lung cancer: lights and shadows
Translational Lung Cancer Research
2013;
2
(1)
:E10-E12
.
(14 January 2013)
Angiogenesis, multitarget kinase inhibitors and non-small cell lung cancer: a lesson from MONET1 trial
Translational Lung Cancer Research
2013;
2
(1)
:E13-E16
.
(14 January 2013)
Perspective
Targeted versus chrono-targeted chemotherapy for inhaled chemotherapy in non-small cell lung cancer
Translational Lung Cancer Research
2013;
2
(1)
:E17-E22
.
(14 January 2013)
Featured Interview
Dr Haiquan Chen: clinical significance of RET fusion gene for patients with NSCLC
Translational Lung Cancer Research
2013;
2
(1)
:E23-E24
.
(14 January 2013)
Case Reports
Recurrent left chest mass: a case report
Translational Lung Cancer Research
2013;
2
(1)
:E25-E28
.
(14 January 2013)
Endobronchial carcinoid tumor in a Crohn disease patient treated with a TNFα inhibitor
Translational Lung Cancer Research
2013;
2
(1)
:E29-E32
.
(14 January 2013)
